ARTICLE

Received 5 Aug 2010 | Accepted 11 Jan 2011 | Published 8 Feb 2011

DOI: 10.1038/ncomms1187

Chromatin remodelling complex dosage modulates transcription factor function in heart development

Jun K. Takeuchi^{1,2,*}, Xin Lou^{3,*}, Jeffrey M. Alexander^{1,4}, Hiroe Sugizaki², Paul Delgado-Olguín¹, Alisha K. Holloway¹, Alessandro D. Mori¹, John N. Wylie¹, Chantilly Munson^{5,6}, Yonghong Zhu³, Yu-Qing Zhou⁷, Ru-Fang Yeh⁸, R. Mark Henkelman^{7,9}, Richard P. Harvey^{10,11}, Daniel Metzger¹², Pierre Chambon¹², Didier Y. R. Stainier^{4,5,6}, Katherine S. Pollard^{1,8}, Ian C. Scott^{3,13} & Benoit G. Bruneau^{1,4,5,14}

Dominant mutations in cardiac transcription factor genes cause human inherited congenital heart defects (CHDs); however, their molecular basis is not understood. Interactions between transcription factors and the Brg1/Brm-associated factor (BAF) chromatin remodelling complex suggest potential mechanisms; however, the role of BAF complexes in cardiogenesis is not known. In this study, we show that dosage of Brg1 is critical for mouse and zebrafish cardiogenesis. Disrupting the balance between Brg1 and disease-causing cardiac transcription factors, including *Tbx5*, *Tbx20* and *Nkx2-5*, causes severe cardiac anomalies, revealing an essential allelic balance between *Brg1* and these cardiac transcription factor genes. This suggests that the relative levels of transcription factors and BAF complexes are important for heart development, which is supported by reduced occupancy of Brg1 at cardiac gene promoters in *Tbx5* haploinsufficient hearts. Our results reveal complex dosage-sensitive interdependence between transcription factors and BAF complexes, providing a potential mechanism underlying transcription factor haploinsufficiency, with implications for multigenic inheritance of CHDs.

¹ Gladstone Institute of Cardiovascular Disease, San Francisco, California 94158, USA. ² Cardiovascular Regeneration, Institute of Molecular and Cellular Biosciences, and Biological Sciences, Graduate School of Sciences, The University of Tokyo Bunkyo-ku, Tokyo 113-0032, JST PRESTO, Japan. ³ Program in Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada. ⁴ Programs in Biomedical Sciences and Developmental and Stem Cell Biology, University of California, San Francisco, California 94143, USA. ⁵ Cardiovascular Research Institute, University of California, San Francisco, California 94158, USA. ⁶ Department of Biochemistry and Biophysics, University of California, San Francisco, California 94158, USA. ⁷ The Mouse Imaging Centre, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada. ⁸ Department of Epidemiology and Biostatistics, University of California, San Francisco, California 94107, USA. ⁹ Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5S 1A8, Canada. ¹⁰ Victor Chang Cardiac Research Institute, Darlinghurst, Sydney 2010, Australia. ¹¹ Faculty of Medicine, University of New South Wales, Kensington 2052, Australia. ¹² Institut de Génétique et de Biologie Moléculaire et Cellulaire, Université de Strasbourg, 1 rue Laurent Fries, Illkirch 67404, France. ¹³ Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada. ¹⁴ Department of Pediatrics, University of California, San Francisco, California 94143, USA. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to B.G.B. (email: bbruneau@gladstone.ucsf.edu).

The transcriptional regulation of organogenesis has been well studied, and in the developing heart, combinatorial interactions between transcription factors are key to robust gene regulation^{1,2}. Importantly, disease-causing mutations in several cardiac transcription factors are the underlying cause of human congenital heart defects (CHDs)^{2,3}. Most of these mutations are predicted to cause haploinsufficiency; however, the mechanistic basis for the aberrant gene expression that results from reduced transcription factor dosage is not known.

Mutations in cardiac transcription factor genes, such as *TBX5*, *NKX2-5* and *GATA4*, all cause dominant inherited human CHD. These factors physically interact with each other, providing an effective mechanism for specific target activation and a potential explanation for their common disease-related haploinsufficiency⁴⁻⁶. *Tbx5*, *Nkx2-5* and *Gata4* also interact with the Swi/Snf-like Brg1/Brm-associated factors (BAF) chromatin remodelling complexes, in part via Baf60c, a cardiac-enriched subunit of the BAF complexes⁷. This interaction is key for the *de novo* induction of cardiac differentiation from embryonic mesoderm⁸, and depletion of Baf60c function leads to impaired heart development⁷.

Identification of Baf60c and other BAF complex subunits that co-assemble to form cell-type-specific complexes has revealed the importance of BAF complexes as instructive factors in differentiation, rather than simply as chromatin-unwinding machines^{7,9-11}. These specific BAF complexes perform discrete functions related to lineage specification and precursor differentiation. However, little is known about dosage sensitivity of tissue-specific BAF complexes or their links to DNA-binding transcription factors that are involved in similar processes.

Mammalian BAF complexes include one of the two ATPases, Brm or Brg1 (ref. 10). Brm is dispensable for development, whereas Brg1 (also known as Smar4) is absolutely essential for broad aspects of development in early mouse embryogenesis^{12,13}. Thus, disrupting the function of Brg1 provides insights into the global function of BAF complexes during development. In the present study, we examined the role of *Brg1* in heart development in mouse and zebrafish and

tested its potential role in modulating the function of disease-related cardiac transcription factors. Our results reveal a dosage-sensitive interdependence between transcription factors and BAF complexes that modulates several aspects of heart formation. We conclude that the disruption of a delicate balance between CHD-causing transcription factors and BAF complexes is likely to be a mechanistic cause of CHDs because of transcription factor haploinsufficiency.

Results

Brg1 is critical for mouse heart development. To assess the importance of Brg1 in the developing mammalian heart, we deleted *Brg1* in developing ventricular myocytes, with a loxP-flanked *Brg1* allele (referred to here as *Brg1*^{fl})¹⁴ and *Nkx2.5::Cre*, which is expressed mainly in ventricular myocytes from E8.5 onwards, with rare sporadic activity in endocardial cells^{15,16} (Fig. 1a and Supplementary Fig. S1). This *Brg1* deletion led to highly variable defects in heart formation (Fig. 1b,c), perhaps partly because of variable and incomplete activity of the Cre-expressing transgene (Fig. 1a and Supplementary Fig. S1). Most embryos did not survive past E10.5; however, a few (two pups from over ten litters) *Nkx2.5::Cre;Brg1*^{fl/fl} mice were born alive. Severely affected embryos had a loss of normal ventricular chamber morphology (Fig. 1b), whereas the least severely affected, which survived to birth, had dilated disorganized ventricles, ventricular septation defects and a double outlet right ventricle (Fig. 1c). Most embryos had reduced chamber size and impaired looping (Fig. 1d). Expression of several cardiac genes was defective in *Nkx2.5::Cre;Brg1*^{fl/fl} embryos (Fig. 1d), including *Nppa* (a marker of chamber myocardium), *Tbx5* (a transcription factor that regulates *Nppa*) and the trabecular growth factor *Bmp10*. Reduced *Bmp10* expression has also been shown in the deletion of *Brg1* using *Sm22a::Cre*, and has been determined to be a critical downstream effector of Brg1-dependent gene regulation¹⁷. Our deletion using *Nkx2.5::Cre*, although variable in its effect, uncovers a broader Brg1-dependent programme of gene expression than that observed with *Sm22a::Cre*, most likely because of the earlier expression of *Nkx2.5::Cre*. Other cardiac genes, such as *Nkx2-5* and *Actc1*, were

Figure 1 | Brg1 is required for early mouse heart formation. (a) Activity of the *Nkx2.5::Cre* transgene, using the Z/EG or RYR reporter, at E8.5, 9.5, 11 and 12.5. Inset for E9.5 embryo shows a ventral four-chamber view. For whole-mount pictures, green signal is the activity of the Z/EG reporter, whereas red signal is the bright-field illumination through a red filter. For the RYR reporter, a cryosection stained for anti-EYFP (green), alpha-tropomyosin (red) and 4,6-diamidino-2-phenylindole (blue) is shown. Original magnification: $\times 25$ (whole-mount pictures), $\times 100$ (sections). (b) Frontal view of OPT reconstructions (left panels), lateral view of OPT reconstructions (middle panels) and histology (rightmost panels) of WT and *Brg1* mutant (*Nkx2.5::Cre;Brg1*^{fl/fl}) mice at E9.5. Arrowhead shows thickened ventricular wall. (c) Histology of postnatal day (P) 1 hearts. Arrow shows membranous ventricular septal defect and double outlet right ventricle in the *Nkx2.5::Cre;Brg1*^{fl/fl} heart. Close-up of the interventricular septum (right panels) shows disorganized septum formation. Original magnification: $\times 100$. (d) Gene expression in WT and *Nkx2.5::Cre;Brg1*^{fl/fl} mice at E8.5 (*Actc1*) or E9.5 (all other genes) shows decreased *Tbx5*, *Nppa*, *Bmp10* and *Hand1* expression. la, left atrium; lb, limb bud; lv, left ventricle; ra, right atrium; rv, right ventricle; v, ventricle; v?, ventricle of ambiguous identity.

Figure 2 | Loss of Brg1 leads to heart development defects in the zebrafish embryos. (a, b) Lateral views at 5 dpf of WT (a) and *brg1*^{s481} (b) zebrafish embryos. Arrowhead in b shows pericardial oedema. (c, d) Frontal views of WT or *brg1*^{s481} zebrafish embryos at 48 hpf, showing myocardium, labelled with *cmlc2*:eGFP (c), and endocardium, labelled with *flk1*:eGFP (d). Original magnification: $\times 100$. (e) Cardiac gene expression in WT and *brg1*^{s481} zebrafish embryos for indicated transcripts (left panels, top to bottom: *cmlc2*, *amhc*, *bmp4* and *notch1b*; right panels, top to bottom: *vmhc*, *nppa*, *tbx2b* and *ncx*). White arrow shows normal absence of *nppa* at the atrioventricular (AV) junction, grey triangles show staining of pacemaker cells, red brackets show normal and expanded domains of AV canal markers (*bmp4* and *tbx2b*). Original magnification: $\times 200$.

expressed normally (Fig. 1d), indicating deregulation of a specific programme in *Nkx2-5::Cre;Brg1*^{fl} hearts.

We conclude that *Brg1* regulates specific programmes of gene expression in the developing heart that are critical for differentiation of cardiac myocytes and cardiac morphogenesis.

Brg1 is critical for zebrafish heart development. The BAF complex is conserved throughout evolution¹⁰. Zebrafishes have a single BAF complex ATPase, *brg1*. *young*, a loss-of-function mutation of *brg1* (refs 18, 19), results in defects in retinal neurogenesis and pericardial oedema, which often indicates a defective heart function. We isolated a new mutation in *brg1*, *brg1*^{s481}, which is predicted to be a null allele (Supplementary Fig. S2); this mutation creates a premature stop codon, predicting a truncation at amino-acid

residue 252 (of 1,627), deleting all functional domains including the ATPase/SNF2 domain and the bromodomains. This mutation fails to complement the published *yng* allele^{18,19} and is phenocopied by morpholino oligonucleotide (MO) treatment (see below), consistent with a null allele. These mutants formed a heart; however, after 48 h of development, the heart became hypoplastic and had severe arrhythmias with sporadic arrests in contraction (Fig. 2a,b; Supplementary Movies 1 and 2). The survival of *brg1* mutant embryos to a late stage is likely related to the presence of maternal *brg1* transcripts¹⁹. To knock down *brg1* in other transgenic lines, translation-inhibiting MOs²⁰ were injected. Knockdown of *brg1* by MO does not alter endocardial differentiation, and vascular development occurred normally (Supplementary Fig. S3). However, the heart chamber displayed severe stenosis (Fig. 2c,d). Co-injection of an MO targeting *p53* was used to investigate a role for cell death in the *brg1* cardiac phenotype²¹. Injection of *p53* MO into *brg1* mutant embryos resulted in an identical cardiac phenotype to that observed in uninjected mutant siblings (Supplementary Fig. S3). Gene expression analysis (Fig. 2e) demonstrated that, although differentiation of both heart chambers occurred properly, *brg1*^{s481} zebrafish had lost the regionalization of *nppa* expression, which marks ‘working’ myocardium in fish and mice²²; this is reminiscent of the loss of *Brg1* in the mouse. Expression of atrioventricular canal-specific genes, including *bmp4*, *tbx2b* and *notch1b*, was abnormal in *brg1*^{s481} embryos, suggesting patterning abnormalities in *brg1* mutant zebrafish embryos. Expression of the $\text{Na}^+/\text{Ca}^{++}$ exchanger (*Ncx*) was elevated in *brg1*^{s481} embryos, which could explain contractility defects in *brg1*^{s481} embryos^{23,24}. We conclude that, in zebrafish, as in the mouse, *brg1* is required for a specific programme essential for cardiac morphogenesis and patterning.

To uncover the cellular mechanisms underlying loss of *brg1* in zebrafish, cardiomyocyte migration, proliferation and shape were analysed. During cardiac cone tilting, an early event in the formation of the zebrafish heart tube, atrial myocardium undergoes left-directed anterior migration²⁵ (Fig. 3a–c; Supplementary Movie 2). In *brg1* morphants, anterior cardiomyocytes, especially those on the right side of the heart, displayed randomized trajectories (Fig. 3d–f; Supplementary Movie 3), resulting in the failure of proper heart jogging, which is indispensable for subsequent heart looping and chamber formation. We monitored the growth of the heart by counting the number of cardiomyocytes at different time points (Fig. 3g–n). At early stages, cell numbers between control and *brg1* morphants were comparable (at 28 hpf, 166 ± 12 ($n=4$) cardiomyocytes in wild type (WT) hearts versus 145 ± 14 in *brg1* morphants ($n=5$)). As development proceeded, however, growth in myocardial cell number obviously lagged in *brg1* morphants and appeared to halt by 48 hpf (251 ± 13 ($n=6$) in WT hearts versus 173 ± 14 in *brg1* morphants ($n=4$); Fig. 3o; Supplementary Movies 4 and 5).

During zebrafish heart development, confined myocardial cell-shape changes are a key parameter in cardiac morphogenesis²². In WT embryos, outer curvature cardiomyocytes became flattened and elongated and were aligned relative to each other (Fig. 3p; Supplementary Movie 6). In *brg1*^{s481} embryos, cardiomyocytes had a cuboidal shape throughout the heart (Fig. 3q; Supplementary Movie 7). Because of the altered and variable cell shape, it is difficult to assess cell size, and thus we have not quantified this parameter; however, cell size did not appear to be grossly altered. As the changes in cell shape require a balance between extrinsic (blood flow) and intrinsic (contractility) biomechanical forces²², we examined the circulation in *brg1*^{s481} embryo (Supplementary Movie 8). The circulation in mutant embryos was slower than that in WT embryos at 36 hpf, but still robust, suggesting that reduced circulation did not cause the abnormal myocyte shapes. Rather, the cell-shape changes in *brg1* mutants may reflect either an intrinsic defect in myocardial morphogenesis and/or be secondary to abnormal heart contractility.

Figure 3 | Defective cardiomyocyte migration and cell shape in zebrafish *brg1* mutants. (a–f) Imaging of atrial cell migration in WT embryos (a–c) and *brg1* morphants (d–f). (a, b, d, e) Dorsal views of heart in Tg(*cm1c2:eGFP^{hu34}*) embryos between 18 and 21 hpf; dotted white lines indicate the embryonic midline. (c, f) Arrows of different colours indicate the trajectories of individual cells. Original magnification: $\times 200$. (g–o) Measurement of cardiomyocyte numbers. Three-dimensional reconstructions of the nuclear DsRed signal from Tg(*cm1c2:dsRedExp-nuc^{hsc4}*) embryos are shown (g–n). The 28 hpf embryos (g, h) are shown in dorsal view, the 36 hpf (i, j), 48 hpf (k, l) and 72 hpf (m, n) embryos are shown in anterior views. (o) Quantitation of cardiomyocyte cell numbers. Data are mean $\pm$ s.d., $n = 5$ –8 embryos; $*P < 0.05$ by *t*-test. Original magnification: $\times 400$. (p, q) Three-dimensional assessment of cell morphologies in Tg(*cm1c2:eGFP^{hu34}*)-expressing hearts that exhibit mosaic expression of Tg(*cm1c2:dsRedExp-nuc^{hsc4}*). Arrows point to representative cells. (p) WT cells transplanted; (q) *brg1⁴⁸¹* cells transplanted. Original magnification: $\times 400$. A, atrium; L, left; R, right; V, ventricle.

CHDs in *Brg1* haploinsufficient mice. The defects upon cardiac-specific deletion of *Brg1* and the phenotype of *brg1* zebrafish show that *Brg1* is critical for specific aspects of cardiac gene expression. As *Brg1*^{+/-} mice are underrepresented after birth¹³, we hypothesized that the partially penetrant lethality in *Brg1*^{+/-} mice might be due to CHDs. We found that 50% of *Brg1*^{+/-} mice died before 3 weeks of age (compared with 0% in WT controls), and in neonatal mice ($n = 10$) we found CHDs such as dilated hearts (5/10), muscular ventricular septal defects (2/10) and incomplete closure of the atrial septum (4/10), a condition known as patent foramen ovale (Fig. 4a). Specific heterozygous deletion of *Brg1* in ventricular myocytes (with *Nkx2.5::Cre*) and cardiac precursors (with *Mef2cAHL::Cre²⁶*) also led to CHDs, indicating that these are not due to nonspecific

Figure 4 | CHDs in *Brg1* heterozygous null mice. (a) Histology of postnatal day 0 WT (left panels) and *Brg1*^{+/-} hearts (right panels), showing dilated chambers, muscular ventricular septal defect (VSD) and patent foramen ovale (PFO) in *Brg1*^{+/-} hearts. Top and bottom panels are planes of section of the same heart at the level of the outflow tract (top panels) and at the level of the atrial septum (bottom panels). Original magnification: $\times 50$. (b) Doppler waveforms of flow at the mitral valve of adult WT and *Brg1*^{+/-} mice, showing altered E and A wave amplitudes in *Brg1*^{+/-} mice. (c) ECG telemetry in WT and *Brg1*^{+/-} mice, showing prolonged PQ interval, sinus pause and second-degree atrioventricular block in *Brg1*^{+/-} mice. (d) Quantitation of selected parameter in WT (grey bars) and *Brg1*^{+/-} (black bars) mice. Units of measure are indicated in parentheses next to the graphed metric title. Data are mean $\pm$ s.d.; $n = 5$; $*P < 0.05$. la, left atrium; lv, left ventricle; ra, right atrium; rv, right ventricle.

effects of loss of *Brg1* outside the heart (Supplementary Fig. S4). The lack of severe defects in *Nkx2.5::Cre;Brg1^{fl/+}* mice (in which heterozygous loss of *Brg1* is only in ventricular myocytes) indicate that the defects in *Brg1*^{+/-} mice are likely to result from combined defects in multiple cardiac cell types. *Brg1*^{+/-} mice that survived the neonatal period had structurally normal hearts, but we also identified specific abnormalities in heart function in adult *Brg1*^{+/-} mice, as determined by high-frequency ultrasound and electrical function (Fig. 4b–d). Haemodynamic anomalies consisted of predominantly impaired cardiac relaxation, as determined primarily by a decrease in E-wave amplitude (Fig. 4b,d). Defects in cardiac electrical function were also found in surviving *Brg1*^{+/-} mice by telemetry electrocardiogram (ECG), which included atrioventricular block, mild prolongation of the QRS complex (indicative of slowed conduction) and occasional sinus node dysfunction (resulting in an irregular heart beat; Fig. 4b–d). We conclude that *Brg1* haploinsufficiency predisposes mice to CHDs and abnormal heart function. This important result identifies a dosage requirement for BAF complexes in specific aspects of cardiac morphogenesis and functional maturation, and suggests a potential mechanistic link to disease-causing mutations in human CHD.

***Brg1* genetically interacts with transcription factor genes.** The morphological and physiological heart defects in $Brg1^{+/-}$ mice are reminiscent of those in $Tbx5$ haploinsufficient mice^{4,27,28}. We hypothesized that *Brg1* might be a critical determinant of the dosage sensitivity of *Tbx5*. To look for a genetic interaction between *Tbx5* and *Brg1*, we generated mice heterozygous for both *Tbx5* and *Brg1* ($Brg1^{+/-};Tbx5^{del/+}$ mice). Compared with $Brg1^{+/-}$ or $Tbx5^{del/+}$ mice, which had normal heart morphologies at E12.5, all $Brg1^{+/-};Tbx5^{del/+}$ mice ($n=6$) had severe defects in heart formation at this stage, including hypoplastic left ventricle and dilated atria (Fig. 5a,b). Although $Brg1^{+/-};Tbx5^{del/+}$ hearts appeared relatively normal at E11.5, this genetic interaction was evident at the level of *Nppa* gene expression at E9.5, which was expressed at normal levels in $Brg1^{+/-}$ mice, at slightly reduced levels in $Tbx5^{del/+}$ mice, but was undetectable in $Brg1^{+/-};Tbx5^{del/+}$ mice (Fig. 5a). Trivial explanations might be that, in $Brg1^{+/-};Tbx5^{del/+}$ mice, the expression of *Tbx5* is much lower than in $Tbx5^{del/+}$ or $Brg1^{+/-}$ mice or that expression of its interacting partners (*Nkx2-5*, *Gata4*) is lower, predisposing the mice to more severe CHDs; this mechanism was discounted by

Figure 5 | Genetic interactions between *Brg1* and cardiac transcription factor genes. (a) *Brg1* and *Tbx5* genetically interact. The top row shows an external view of hearts from E12.5 WT, $Brg1^{+/-}$, $Tbx5^{del/+}$ and $Brg1^{+/-};Tbx5^{del/+}$ embryos; the bottom row shows expression of *Nppa* at E9.5 for the same genotypes. Original magnification: $\times 50$. (b) Histology of E11.5 WT and $Brg1^{+/-};Tbx5^{del/+}$ embryos. $Brg1^{+/-}$ or $Tbx5^{del/+}$ embryos are indistinguishable from WT. Asterisk indicates atrioventricular cushion and arrowhead indicates interventricular septum. Original magnification: $\times 100$. (c) *Brg1* and *Tbx5* interactions in zebrafish. Tg(*cmlc2:eGFP^{wtu34}*) control (WT) or MO-injected embryos are shown in ventral-anterior views at 72 hpf. *Brg1*MO: MO directed against *Brg1*; *Tbx5*MO: MO directed against *Tbx5*. All MOs were injected at 1 ng. Percentages in the *Brg1*MO and *Tbx5*MO show the percentage of normal hearts. The graph shows the percentage of phenotypes observed in double knockdown experiments ($n=74, 91$ and 126 for *brg1*, *tbx5* and *brg1+tbx5* morpholino injections, respectively). Original magnification: $\times 400$. (d) *Brg1* genetically interacts with *Tbx5*, *Nkx2-5* and *Tbx20*. Histology of E12.5 hearts shows specific defects in $Brg1^{+/-};Tbx5^{del/+}$, $Brg1^{+/-};Nkx2-5^{+/-}$ and $Brg1^{+/-};Tbx20^{+/-}$ embryos, compared with WT. *Nkx2-5^{+/-}* and *Tbx20^{+/-}* hearts are structurally identical to WT hearts. Asterisk indicates atrioventricular cushion and arrow indicates atrial septum (as). Original magnification: $\times 100$. (e) Summary of microarray analysis performed on E11.5 hearts of the indicated genotypes. Venn diagrams show the number of altered transcripts for each genotype, using a statistical cutoff of $P < 0.01$ and fold change > 0.3 . la, left atrium; lv, left ventricle; ot, outflow tract; ra, right atrium; rv, right ventricle.

quantitative reverse transcription-PCR and microarray analysis that showed similar levels of *Tbx5*, *Nkx2-5* and *Gata4* messenger RNA (mRNA) in $Brg1^{+/-}$ and $Brg1^{+/-};Tbx5^{del/+}$ hearts at E11.5 (Supplementary Fig. S5 and Supplementary Data 1).

In zebrafish, mutation of *tbx5* in the *heartstrings* mutant²⁹ leads to defects in heart looping and progressive deterioration of the heart. The similarity between *tbx5* and *brg1* mutants in the fish raised the possibility that genetic interactions between these two genes may exist also in zebrafish. We performed double knockdown of *brg1* and *tbx5* via MOs. When 1 ng *brg1* or *tbx5* morpholino was injected, the heart developed normally in all cases (Fig. 5c). In contrast, co-injection of *brg1* and *tbx5* morpholino (1 ng each) resulted in 52% of embryos displaying a severe *heartstrings*-like phenotype and 44% of embryos having a milder unlooped, tube-like heart phenotype ($n=120$; Fig. 5c), demonstrating a clear and conserved genetic interaction between *brg1* and *tbx5*.

We utilized the variable dose dependency of other critical cardiac transcription factors in the mouse to test further genetic interactions with *Brg1*. Although *Tbx5* haploinsufficiency in the mouse mimics CHDs in humans⁴, *Nkx2-5* heterozygous mice display only very mild aspects of CHDs caused by human *NKX2-5* mutations^{30,31}, and *Tbx20* haploinsufficiency does not result in any detectable heart defects³². We generated compound heterozygous mice for *Brg1* and for either *Tbx5*, *Nkx2-5* or *Tbx20*; all mouse mutations are loss-of-function alleles with no known dominant activity. In all three cases, dramatic and specific defects in heart formation were observed in all compound heterozygous mice ($n=4-8$) at E12.5 (Fig. 5d), and no compound heterozygous mice survived past E14.5. Defects included severe loss of cardiac cushion formation ($Tbx5^{+/-};Brg1^{+/-}$ and $Brg1^{+/-};Nkx2-5^{+/-}$), thinned atrial walls ($Tbx5^{+/-};Brg1^{+/-}$, $Tbx20^{+/-};Brg1^{+/-}$), hypoplastic ventricles ($Tbx5^{+/-};Brg1^{+/-}$, $Nkx2-5^{+/-};Brg1^{+/-}$) and thinned ventricular walls ($Nkx2-5^{+/-};Brg1^{+/-}$, $Tbx20^{+/-};Brg1^{+/-}$). *gata5* mutant fishes also have heart defects³³, and mouse *Gata4*, the functional homologue of zebrafish *gata5*, interacts with BAF complexes^{7,8}; we also observed an interaction of *brg1* and *gata5* low-dose MOs, supporting a more general importance of dose-dependent interactions between *Brg1* and cardiac transcription factors (Supplementary Fig. S2).

These strong genetic interactions between *Brg1* and cardiac transcription factor genes in mouse and zebrafish demonstrate a finely regulated interdependency between cardiac DNA-binding transcription factors and BAF chromatin remodelling complexes.

Programmes regulated by *Brg1* and cardiac transcription factors.

The genetic interaction between *Brg1* and cardiac transcription factor genes could be a result of a genetic programme common to all transcription factors that is sensitive to *Brg1* levels or, alternatively, *Brg1* may potentiate each transcription factor's specific genetic programme. To address this question, we performed transcriptional profiling of E11.5 hearts from mice heterozygous for deletions of *Brg1*, *Tbx5* or *Nkx2-5*, and mice that were compound heterozygotes for *Brg1* and each transcription factor gene. We observed varying degrees of overlap between the sets of genes that were altered by decreased dosages of *Brg1*, *Tbx5* and *Nkx2-5*, indicating some specificity to the programmes that are regulated by these factors (Fig. 5e and Supplemental Data 1, and quantitative RT-PCR (QRT-PCR) validation in Supplementary Fig. S5). Clustering analysis defined specific groups of genetic interactions (Fig. 6a,b), indicating considerable complexity to the genetic interactions between *Nkx2-5* or *Tbx5* and *Brg1*. For example, some genes were altered mostly in compound heterozygous hearts (clusters a, m, g, t). These genes are more resistant to an imbalance between *Brg1* and the DNA-binding factors, but still rely on the balance of *Brg1* and *Tbx5* or *Nkx2-5* for their normal regulation. Imbalance in the expression of these sets of genes is likely to be key for the compound heterozygous phenotype observed between *Brg1* and *Tbx5* or *Nkx2-5*.

Perhaps more surprisingly, many genes that were altered in single heterozygous (*Nkx2-5^{lacZ/+}*, *Brg1^{+/-}* or *Tbx5^{del/+}*) hearts compared with WT hearts were not significantly altered in compound heterozygous (*Nkx2-5^{lacZ/+};Brg1^{+/-}* or *Tbx5^{del/+};Brg1^{+/-}*) hearts (clusters d, e, l, n, o and u in Fig. 6a,b). One possible interpretation of this striking interaction is that the relative levels of *Nkx2-5* (or *Tbx5*) and *Brg1* need to be maintained for normal expression of this set of genes, and that loss of one allele of either *Nkx2-5* or *Brg1* in single heterozygotes upsets this balance, leading to an allelic ratio of 2:1 or 1:2; however, in *Nkx2-5^{lacZ/+};Brg1^{+/-}* hearts the balance is restored (a 1:1 allelic ratio). This implies that the relative levels between the DNA-binding factors (*Tbx5* and *Nkx2-5*) and *Brg1* is critical for a large set of genes.

The types of genes identified in the transcriptional profiling assays were from a wide range of functional classes, as exemplified from statistical exploration of Gene Ontology classifications that revealed broad classes of transcripts enriched in specific clusters (Fig. 6). Several genes important for heart development were identified in the different clusters of differentially regulated genes, including several previously identified as altered in *Nkx2-5*- or *Tbx5*-deficient hearts^{31,34,35}. One particular novel set of transcripts was of interest: in *Nkx2-5^{lacZ/+}* and *Brg1^{+/-}* hearts, we measured a clear increase in expression of several genes associated with the haematopoietic programme, including key regulators of this programme such as *Gata1*, *Klf1* and *Tal1*. This implies that *Nkx2-5/Brg1* suppresses haematopoietic differentiation in the embryonic heart.

It is difficult to precisely link the contribution of the different genetic programmes regulated by individual factor dosage and combinatorial dosage to the heart defects in each genetic modification, especially with only one snapshot in developmental time. Furthermore, many of the affected transcripts are likely to be due to indirect effects. However, it is clear that overlapping programmes are sensitive to the dosage of *Brg1* and the cardiac transcription factor genes.

Reduced promoter occupancy by *Brg1* in mutant hearts. Genetic interactions between *Brg1* and cardiac transcription factors may reflect a direct physical interaction that is sensitive to the dosage of each factor, in one or multiple cell types, as well as interactions

between various cell types in which one factor is haploinsufficient, and another cell type in which the interacting factor is haploinsufficient. To address the former possibility, we performed chromatin immunoprecipitation (ChIP) for *Brg1* on E9.5 hearts from WT, *Tbx5^{del/+}*, *Brg1^{+/-}* and *Tbx5^{del/+};Brg1^{+/-}* embryos at the cardiomyocyte-specific *Nppa* and *Gja5* promoters (Fig. 7a). We found that at the *Nppa* gene, *Brg1* occupancy was reduced in *Brg1^{+/-}* hearts, consistent with a limiting amount of *Brg1*, and that at both *Nppa* and *Gja5*, *Brg1* occupancy was reduced in *Tbx5^{del/+}* hearts, indicating that reduced levels of *Tbx5* directly result in reduced occupancy of *Brg1* (Fig. 7b). *Brg1* occupancy on both promoters was further reduced in *Tbx5^{del/+};Brg1^{+/-}* embryos, suggesting that the interdependency of *Tbx5* and *Brg1* is partly compensated by interactions with other factors, perhaps other transcription factors that can interact with BAF complexes. These results provide a mechanism for some of the dosage-related relationships between *Tbx5* and *Brg1* on *Tbx5* target genes, and support the notion that at least some of the effects of the genetic interaction between *Tbx5* and *Brg1* reflect cell-autonomous direct interactions.

***Brg1*-dependent transcriptional activation *in vitro*.** We investigated whether transcriptional activation of cardiac genes directly requires the function of *Brg1*. We previously showed that *Tbx5*, *Nkx2-5*, *Gata4* and the BAF complex subunit *Baf60c* can activate cardiac gene expression in non-cardiac mesoderm⁸. We found that co-transfection of NIH3T3 fibroblasts with *Tbx5*, *Nkx2-5* and *Gata4* expression constructs could robustly induce *de novo* the cardiac-specific gene *Nppa*, a marker of differentiated cardiomyocytes, the promoter of which is well characterized as a target of these transcription factors (Fig. 7c) (refs 4, 36). As *Baf60c* is expressed in NIH3T3 fibroblasts, exogenous *Baf60c* did not enhance the effect (data not shown). Other cardiac genes examined were not induced by this combination of factors. To determine the requirement for *Brg1* in the *de novo* activation of *Nppa*, we depleted *Brg1* with endoribonuclease prepared small interfering RNAs (esiRNAs)³⁷. esiRNAs directed against *Brg1* resulted in an ~50% decrease in *Brg1* protein level (Fig. 7d). Decreased levels of *Brg1* completely prevented *Nppa* activation by cardiac transcription factors (Fig. 7e,f), suggesting that this transcriptional activation is dependent on limiting amounts of functional *Brg1*-containing BAF complexes.

Discussion

We demonstrated a critical, conserved and dosage-sensitive role for the BAF chromatin remodelling complex ATPase *Brg1* in vertebrate heart development. Our results further show an important interdependency between BAF complexes and disease-related cardiac transcription factors, which suggests a mechanism for CHDs caused by mutations in these transcription factor genes and implications for multigenic inheritance of CHDs.

In mouse and zebrafish, *Brg1* is required for important and specific aspects of heart development. In particular, chamber morphogenesis is disrupted in both mice and fish lacking *Brg1*, and proliferation of cardiac progenitors is reduced. A key subset of cardiac genes was affected by the loss of *Brg1*, consistent with specific roles for BAF complexes in differentiation of other cell types^{9,14,19,38–42}. In many of these cases, *Brg1* is required for differentiation after specification. Our results support a clear role for *Brg1* in cardiac differentiation. As the function of *Gata4*, *Nkx2-5* and *Tbx5* relies on BAF complexes, in part via *Baf60c*^{7,8}, loss of *Brg1* likely affects target genes primarily by reducing the activation potential of cardiac transcription factors. Loss of *brg1* in zebrafish demonstrates a strikingly conserved role for BAF complexes in vertebrate cardiac development. The morphogenetic and gene expression defects in *brg1* mutant fish closely resemble that seen in mice lacking *Brg1*, suggesting that the gene networks regulated by BAF complexes are well conserved in vertebrate evolution.

Figure 6 | Clustering analysis of altered gene expression. (a) Clustering analysis of altered transcripts from *Nkx2-5^{+/-}* (N), *Brg1^{+/-}* (B) and compound heterozygotes, *Nkx2-5^{+/-};Brg1^{+/-}* (NB) E11.5 hearts. Heart maps for all statistically significant clusters indicate the average value for each group. All biological replicates within groups were included in cluster analyses; figures were made by taking the mean for each group. Box plots for a selection of clusters show the median (middle line), third and first quartile (top and bottom (hinges) of the boxes); the ‘whiskers’ extend 1.5× the length of the box, with other points (outliers) plotted as circles. Statistically significantly overrepresented Gene Ontology (GO) categories (adjusted $P < 0.01$) are shown. Genotypes are shown on the x axis; y axis shows log 2 fold change from WT. (b) Clustering analysis as in B, but for transcripts from *Tbx5^{del/+}* (T), *Brg1^{+/-}* (B) and compound heterozygotes, *Tbx5^{del/+};Brg1^{+/-}* (TB) E11.5 hearts.

Notably, mice heterozygous for a deletion of *Brg1* have heart defects. This important finding indicates that *Brg1* is haploinsufficient in the heart. Haploinsufficiency of *Brg1* has been reported in the brain¹³ and immune system⁴³, indicating that certain cell types are sensitive to the dosage of *Brg1*. The important dose dependency of *Brg1* function in cardiogenesis shows that, as for DNA-binding transcription factors, normal formation of the heart relies on precise levels of functional BAF complexes. Furthermore, the genetic interaction between *Brg1* and several cardiac transcription factor genes

shows that transcription factor function is intimately linked to levels of Brg1. The resulting CHDs are likely to reflect these interactions in multiple cell types. Our promoter occupancy data indicate that, for at least a portion of co-regulated genes, a direct cell-autonomous dosage-related interaction exists. Specific genetic programmes are sensitive to the dosage of each transcription factor, and there is considerable complexity in the genomic regulation of gene expression by Brg1 and cardiac transcription factors. In some cases, a clear interrelationship exists between the dosage effects of either factor,

Figure 7 | Direct interactions between Brg1 and cardiac transcription factors. (a) Diagram indicating the location of primer pairs for amplification of immunoprecipitated chromatin-associated DNA for *Nppa* and *Gja5*. Locations of conserved T-box-binding elements (TBE), GATA factor-binding sites (GATA) and Nkx2-5-binding sites (NKE) are shown. ATG: start codon; TGA: translational stop codon. Nucleotide positions shown are relative to start codon. (b) ChIP of Brg1 at the *Nppa* or *Gja5* promoters from E9.5 hearts of the indicated genotypes. On the left are EtBr-stained gels showing amplification, and quantitation by QPCR is shown in the graphs on the right. Data are mean ± s.e.; n = 3; *P < 0.05. (c) Quantitation of *Nppa* mRNA in NIH3T3 fibroblasts transfected with combinations of Tbx5, Nkx2-5 and Gata4. Data are mean ± s.e.; n = 3; *P < 0.05 versus mock transfection. (d) Western blot to measure reduction of Brg1 protein levels by anti-Brg1 esiRNAs. Actin is a loading control. (e) Quantitation of *Nppa* mRNA in NIH3T3 fibroblasts transfected with Tbx5, Nkx2-5 and Gata4, with or without esiRNAs targeting Brg1, or control esiRNAs. TFs = Tbx5, Gata4 and Nkx2-5. Data are mean ± s.e.; n = 3; *P < 0.05 versus mock transfection; **P < 0.05 esiBrg1⁺ versus esiBrg1⁻. (f) Brg1 mRNA levels in the same samples as in **c**. Data are mean ± s.e.; n = 3; **P < 0.05 esiBrg1⁺ versus esiBrg1⁻.

resulting in a more profound effect in embryos haploinsufficient for *Brg1* and *Nkx2-5* or *Tbx5*. In other words, diminution of levels of one factor will reduce that factor's chance of interaction with BAF complexes, and this can be accentuated when Brg1 levels are also lower. Our molecular data support a model (Fig. 8, model a) for

Figure 8 | Models for the interaction between DNA-binding transcription factors and Brg1. Two models for the interaction between DNA-binding transcription factors and Brg1. Model (a) is based on the dosage-sensitive interrelationship between DNA-binding transcription factors (represented by Tbx5) and Brg1. In *Brg1*^{+/-} hearts, some Tbx5-binding events are not accompanied by concomitant Brg1 binding, resulting in decreased gene expression. In *Tbx5*^{+/-} hearts, Brg1 can only interact with one of two potential Tbx5-binding events, but may still interact more weakly with other DNA-binding transcription factors (X). In *Tbx5*^{+/-}; *Brg1*^{+/-} hearts, all quantitative interactions are impaired, leading to further reduction in target gene expression. Model (b) is based on the normalization of gene expression in *Tbx5*^{+/-}; *Brg1*^{+/-} and *Nkx2-5*^{+/-}; *Brg1*^{+/-} hearts, and is based on the allelic balance between the two genes. In *Brg1*^{+/-} hearts, the ratio of Tbx5 to Brg1 alleles is now 2:1, which allows some Tbx5-binding events to interact with other factors, including a hypothetical repressor protein (Y). In *Tbx5*^{+/-} hearts, the ratio of Tbx5 to Brg1 alleles is now 1:2, which allows some Brg1-binding events to interact with other factors, including a hypothetical repressor or sequestering protein (Z). In *Tbx5*^{+/-}; *Brg1*^{+/-} hearts, the balance is restored to 1:1, eliminating the potential for other interactions.

direct interactions between Brg1 and cardiac transcription factors, and imply that reduced recruitment of BAF complexes may be a significant molecular mechanism underlying transcription factor haploinsufficiency in congenital heart disease.

The observation that expression levels of several transcripts that are altered in heart heterozygous for a null allele of *Nkx2-5*, *Tbx5* or *Brg1* are restored to normal or near-normal levels in *Nkx2-5*^{lacZ/+}; *Brg1*^{+/-} or *Tbx5*^{lacZ/+}; *Brg1*^{+/-} compound heterozygous hearts indicates that for some genes, the relative allelic balance of *Nkx2-5* (or *Tbx5*) and *Brg1* may be more important than their absolute levels. The mechanism underlying this dosage interdependence is not known, but may include increased potential for interaction with other proteins that would alter the functional output on target genes (Fig. 8, model b). Thus, haploinsufficiency of cardiac transcription factors in CHDs is predicted to result in an imbalance between transcription factors and BAF complexes, likely resulting in impaired transcriptional activation at loci sensitive to this balance. The reason for distinct dosage-sensitive responses from one group of genes to the next is not known, but perhaps the chromatin status of some genes requires different dosage-related interactions between BAF complexes and DNA-binding transcription factors.

We cannot discern which specific group of genes, between those that respond more in the compound heterozygotes, those that return to WT levels in compound versus single heterozygotes, or combinations thereof, is responsible for the phenotypic output of transcription factor or *Brg1* haploinsufficiency. It is likely that deregulation of many different genes in various functional classes would be responsible for the complex altered morphology and function that we observe.

In conclusion, we demonstrated a critical requirement for Brg1 in the development of the vertebrate heart, and importantly showed that there exists a fine balance between Brg1 levels and those of cardiac transcription factors that have been implicated in human CHD. The genetic interactions between *Brg1* and cardiac transcription factor

genes predict that, in the developing heart, maintaining relative levels of BAF complexes and transcription factors is critical for the timely and precise activation of groups of genes during development. In human congenital heart disease, disruption of these dosage-sensitive interactions would predict the impaired activation of specific gene networks that are essential for specific aspects of cardiac morphogenesis and function. We propose that an imbalance in this relationship is a molecular basis underlying CHDs caused by mutations in cardiac transcription factors. Although such a finely regulated interrelationship is perhaps more prone to disruption, it confers significant advantages in the fine quantitative regulation of transcript levels, which is an essential component of complex morphogenesis. These results further underscore the potential for multigenic effects on dominant mutations, and suggest that polymorphisms in BAF complex subunit genes, including but not restricted to *Brg1*, may modulate the penetration and phenotypic consequence of disease-causing mutations in transcription factor genes in human populations.

Methods

Mouse strains and embryology. The following mouse strains were used: *Brg1*^{12/14}, *Nkx2-5::Cre*¹⁵, *Mef2cAHH::Cre*²⁶, *Tbx5^{del} +4*, *Nkx2-5^{lacZ} +35*, *Tbx20^{+/−32}*, *Z/EG*⁴⁴ and *RYR*⁴⁵. *Brg1*^{+/−} mice were generated by crossing *Brg1*^{12/14} mice with *Elia-Cre* mice⁴⁶. For all experimental analyses, at least three embryos per genotype were examined. All animal experiments were conducted following guidelines established and approved by the UCSF Institutional Animal Care and Use Committee, and in accordance with best practices outlined by the Canadian Council on Animal Care and licensed by Lab Animal Services at the Hospital for Sick Children.

Analysis of protein and mRNA expression. Immunostaining and *in situ* hybridization procedures were carried out by standard protocols. For immunostaining, cryosections were incubated with primary antisera against enhanced green fluorescent protein (EGFP; Abcam ab13970, 1:300) and with alpha-tropomyosin (CH1 monoclonal, Hybridoma bank, 1:50), followed by incubation with Alexa Fluor 488-coupled goat-anti-chicken immunoglobulin (Ig) G (Invitrogen A11039, 1:200) and Alexa Fluor 594-coupled goat anti-mouse IgG (Invitrogen A110320), and were mounted with Prolong gold with 4,6-diamidino-2-phenylindole (Invitrogen), to stain nuclei. *In situ* hybridization by whole mount or on 10 µm paraffin sections was performed using previously described protocols⁴⁷. RNA probes were labelled with digoxigenin-labelled UTP, hybridized to samples and after washes were incubated with alkaline phosphatase-coupled anti-digoxigenin antisera (Roche); colorimetric detection was carried out by incubation with BM purple (Roche). Optical projection tomography (OPT) was performed as described⁷ using embryos labelled for alpha-cardiac actin (*Actc*) by fluorescent *in situ* hybridization (using the TSA amplification system, Amersham). OPT images were acquired in the GFP channel for tissue autofluorescence, and in the red channel for *Actc* fluorescence. Three-dimensional reconstructions were analysed and rendered in Amira 4.0 (Visage Imaging). QRT-PCR was performed with Taqman probe sets (Supplementary Table S1).

Cardiac physiology. Cardiac function was assessed by high-frequency ultrasound and telemetry ECG^{42,7}. For ultrasound assessment of cardiac function, a high-frequency ultrasound imaging system (Vevo 660, VisualSonics) with a 30 MHz transducer was used for *in vivo* evaluation of cardiac morphology and function as previously described in detail²⁷. Mice were anaesthetized with isoflurane at 1.5% by face mask, and body temperature was maintained at ~37 °C. An M-mode recording of the left ventricle was made in long-axis view and analysed for wall thickness and chamber dimension. Fractional shortening was also calculated as a measure of left ventricular systolic function. Mitral Doppler flow spectrum was recorded in apical four-chamber view, with the Doppler sample volume placed at the centre of mitral orifice and at the tip level of the valves for the highest velocities. The peak velocities of the early ventricular filling wave (E wave) and the late ventricular filling wave caused by atrial contraction (A wave) were measured, and their ratio was calculated. The left ventricular systolic and diastolic time intervals were also measured, including the isovolumic relaxation time, ventricular diastolic filling time, isovolumic contraction time and ventricular ejection time. All parameters were averaged for three cardiac cycles.

For ECG telemetry, telemetry devices (DSI) were implanted subcutaneously dorsally under anaesthesia (sodium pentobarbital, 0.033 mg g^{−1} i.p.), and the leads were placed in lead II conformation. Following a 72 h recovery period, mice housed in individual cages were placed on telemetry detection platforms and continuous ECG tracings were acquired for 24 h. ECGs were manually examined for arrhythmias. Ultrasound measurements and ECG intervals were calculated during periods of regular sinus rhythm.

Zebrafish embryology and genetics. The *Brg1*¹⁴⁸¹ allele was identified in a diploid ENU mutagenesis screen for mutations affecting endodermal organ morphogenesis⁴⁸. A C-to-T base-pair change at position 754 in the *Brg1* (*smarca4*) coding sequence

creates a premature STOP codon at amino acid 252. MOs targeting *Brg1* and *p53* have been previously published and validated^{20,21}. RNA *in situ* hybridization probes for *myl7/cmlc2*, *nppa*, *bnp4*, *tbx2b* and *notch1b* have been characterized^{49,50}. For the *ncx1h* (*slc8a1a*) probe, a 560 bp PCR product amplified from cDNA was used as a template.

For mosaic labelling of cardiomyocytes, embryos from Tg(*cmlc2:eGFP^{mw34}*)^{+/+} in-crosses were injected at the one-cell stage with 10 pg of pBISceI-cmlc2:dsRed plasmid DNA with I SceI enzyme (NEB) in I SceI buffer.

For time-lapse analysis, Tg(*cmlc2:eGFP*) control embryos or morphants were mounted in agarose, and imaged at 28.5 °C using a 25× water objective. To count cardiomyocytes at various stages, we used the Tg(*cmlc2:dsRedExp-nuc^{hscf}*) line. Mounted embryos were imaged with a 40× water immersion lens. Sequential confocal images were taken with a standardized step size of 0.65 µm in the z-direction. Quantification of myocardial cells, cell migration tracking and three-dimensional reconstructions of confocal stacks were carried out using Velocity (Improvision).

Microarrays and statistical analysis. Affymetrix mouse Gene ST 1.0 arrays were hybridized and scanned according to the manufacturer's recommendations. Raw intensities from CEL files were analysed using Affymetrix Power Tools (APT, version 1.10.1) to generate robust multiarray average⁵¹ expression intensities on a log-2 scale for each probe set and various quality metrics. The probe intensities were background-corrected, quantile-normalized and summarized for each probe set using a robust fit of linear models. Linear models were fitted for each gene to estimate genotype effects and associated significance using the limma package⁵² in R/Bioconductor. Because sample sizes are often small in microarray experiments, the eBayes function in limma computes s.e. that are moderated across all genes on the array. The interpretation of the moderated t-statistics is the same as an ordinary t-statistics. *Nkx2-5/Brg1* and *Tbx5/Brg1* experiments were analysed separately using 2×2 factorial models. Linear contrasts were used to extract comparisons of interest. P-values were adjusted for multiple testing by controlling for false-discovery rate using the Benjamini–Hochberg method⁵³. Genes differentially expressed > 1.3-fold with adjusted *P* < 0.01 were considered significantly different between groups. QRT-PCR and ChIP data were analysed by analysis of variance, followed by *post hoc* Tukey's test; *P* < 0.05 was considered significant. Pairwise comparisons were made using *t*-test; *P* < 0.05 was considered significant.

Clustering and pathway analysis. Genes that were declared to be differentially expressed were subjected to unsupervised cluster analysis with the R package HOPACH⁵⁴. All biological replicates within groups were included in cluster analyses. Pearson's correlations between genes were used as the distance metric, and default settings were used for other parameters. Clusters with similar expression patterns between genotypes were collapsed for further analysis. GOElite (www.genmapp.org/go_elite/go_elite.html/) was used to identify over-represented gene ontology terms and pathways among the sets of differentially expressed genes. All genes that were subjected to expression analysis were used as the 'denominator' gene list for detecting overrepresentation. Null distributions were derived by permutation (*n* = 2000). Significance was assessed using false-discovery rate-adjusted *P*-values.

Cell culture and ChIP. NIH/3T3 mouse embryonic fibroblasts were seeded in a 24-well format at 40,000 cells per well; 2 days after seeding, cells were transfected using Lipofectamine 2000 reagent (Invitrogen) with a combination of HA-Tbx5, myc-GATA4 and FLAG-Nkx2-5 overexpression plasmids (200 ng) or empty pcDNA3.1⁺ (600 ng total). esiRNAs were generated as described³⁷; briefly, regions of EGFP or *Brg1* were amplified by PCR (using the following primers: eGFP_esi1 (forward): 5'-TAATACGACTCACTATAGGGCGGTAAACGGCCACAGTTC-3'; eGFP_esi2 (reverse): 5'-TAATACGACTCACTATAGGGATGGGGGTGTCTCTGCTGGTA-3'; *Brg1* esiRNA (forward): 5'-GGGCGGGTGTGTCCCTGTACACACACACACC-3'; *Brg1* esiRNA (reverse): 5'-GGGCGGGTCTGCAGCTCTTGAAGATAGTGG-3'). *Brg1* PCR products were further amplified with an adaptor primer containing T7 sequences (5'-TAATACGACTCACTATAGGGAGACCACGGGCGGGT-3'). EGFP and *Brg1* products were then purified using a Qiagen PCR Clean Up kit and were *in vitro* transcribed using T7 RNA polymerase (Roche). Transcribed RNA was annealed to yield double stranded RNA. After purification (Roche; Quick Spin Columns), 10 µg of double stranded RNA was subjected to digestion using purified glutathione S-transferase (GST)-RNase III fusion protein and purified by ethanol precipitation to generate pools of 21 bp esiRNAs.

In knockdown experiments, 450 ng of either esiGFP or esiBrg1 was transfected. Relative expression was determined by quantitative PCR using TaqMan probes against *Nppa* and *Brg1*; expression was normalized to β-actin (probe-set details in Supplementary Table S1). Each reaction was performed in technical triplicate.

ChIP was performed as previously described⁸, using chromatin isolated from E12.5 embryonic hearts, with anti-Brg1 antiserum (Upstate 07-478) or normal rabbit IgG (Santa Cruz 2027), using 1 µg of antiserum. PCR was performed using the following primers: *Nppa*-595F: 5'-TCTTTCACCTGACTGCTAACA-3', *Nppa*-12R: 5'-ACGATCTCCCGTTTATAG-3'; *Gja5*-F1: 5'-ACGACTGTGGCAGCA GGTGTCTGC-3', *Gja5*-R1: 5'-AGAAGCAGCAGGTGCCCTTCCCCT-3'. Amplicons were 573 bp long for *Nppa* and 583 bp long for *Gja5*. Quantification was performed using the same primers and SYBR green quantification.

References

- Olson, E. N. Gene regulatory networks in the evolution and development of the heart. *Science* **313**, 1922–1927 (2006).
- Srivastava, D. Making or breaking the heart: from lineage determination to morphogenesis. *Cell* **126**, 1037–1048 (2006).
- Bruneau, B. G. The developmental genetics of congenital heart disease. *Nature* **451**, 943–948 (2008).
- Bruneau, B. G. *et al.* A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. *Cell* **106**, 709–721 (2001).
- Garg, V. *et al.* GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. *Nature* **424**, 443–447 (2003).
- Hiroi, Y. *et al.* Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. *Nat. Genet.* **28**, 276–280 (2001).
- Lickert, H. *et al.* Baf60c is essential for function of BAF chromatin remodelling complexes in heart development. *Nature* **432**, 107–112 (2004).
- Takeuchi, J. K. & Bruneau, B. G. Directed transdifferentiation of mouse mesoderm to heart tissue by defined factors. *Nature* **459**, 708–711 (2009).
- Lessard, J. *et al.* An essential switch in subunit composition of a chromatin remodeling complex during neural development. *Neuron* **55**, 201–215 (2007).
- Ho, L. & Crabtree, G. R. Chromatin remodelling during development. *Nature* **463**, 474–484 (2010).
- Bruneau, B. G. Chromatin remodeling in heart development. *Curr. Opin. Genet. Dev.* **20**, 505–511 (2010).
- Reyes, J. C. *et al.* Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). *EMBO J.* **17**, 6979–6991 (1998).
- Bultman, S. *et al.* A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. *Mol. Cell* **6**, 1287–1295 (2000).
- Indra, A. K. *et al.* Temporally controlled targeted somatic mutagenesis in embryonic surface ectoderm and fetal epidermal keratinocytes unveils two distinct developmental functions of BRG1 in limb morphogenesis and skin barrier formation. *Development* **132**, 4533–4544 (2005).
- McFadden, D. G. *et al.* The Hand1 and Hand2 transcription factors regulate expansion of the embryonic cardiac ventricles in a gene dosage-dependent manner. *Development* **132**, 189–201 (2004).
- Ieda, M. *et al.* Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. *Dev. Cell* **16**, 233–244 (2009).
- Hang, C. T. *et al.* Chromatin regulation by Brg1 underlies heart muscle development and disease. *Nature* **466**, 62–67 (2010).
- Link, B. A., Fadool, J. M., Malicki, J. & Dowling, J. E. The zebrafish young mutation acts non-cell-autonomously to uncouple differentiation from specification for all retinal cells. *Development* **127**, 2177–2188 (2000).
- Gregg, R. G., Willer, G. B., Fadool, J. M., Dowling, J. E. & Link, B. A. Positional cloning of the young mutation identifies an essential role for the Brahma chromatin remodeling complex in mediating retinal cell differentiation. *Proc. Natl Acad. Sci. USA* **100**, 6535–6540 (2003).
- Eroglu, B., Wang, G., Tu, N., Sun, X. & Mivechi, N. F. Critical role of Brg1 member of the SWI/SNF chromatin remodeling complex during neurogenesis and neural crest induction in zebrafish. *Dev. Dyn.* **235**, 2722–2735 (2006).
- Plaster, N., Sonntag, C., Busse, C. E. & Hammerschmidt, M. p53 deficiency rescues apoptosis and differentiation of multiple cell types in zebrafish flathead mutants deficient for zygotic DNA polymerase delta1. *Cell Death Differ.* **13**, 223–235 (2006).
- Auman, H. J. *et al.* Functional modulation of cardiac form through regionally confined cell shape changes. *PLoS Biol.* **5**, e53 (2007).
- Bolck, B. *et al.* Na⁺/Ca²⁺ exchanger overexpression impairs frequency- and ouabain-dependent cell shortening in adult rat cardiomyocytes. *Am. J. Physiol. Heart Circ. Physiol.* **287**, H1435–H1445 (2004).
- Reuter, H., Han, T., Motter, C., Philipson, K. D. & Goldhaber, J. I. Mice overexpressing the cardiac sodium-calcium exchanger: defects in excitation-contraction coupling. *J. Physiol.* **554**, 779–789 (2004).
- Baker, K., Holtzman, N. G. & Burdine, R. D. Direct and indirect roles for nodal signaling in two axis conversions during asymmetric morphogenesis of the zebrafish heart. *Proc. Natl Acad. Sci. USA* **105**, 13924–13929 (2008).
- Verzi, M. P., McCulley, D. J., De Val, S., Dodou, E. & Black, B. L. The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field. *Dev. Biol.* **287**, 437–449 (2005).
- Zhou, Y. Q. *et al.* Abnormal cardiac inflow patterns during postnatal development in a mouse model of Holt-Oram syndrome. *Am. J. Physiol. Heart Circ. Physiol.* **289**, H992–H1001 (2005).
- Zhu, Y. H. *et al.* Tbx5-dependent pathway regulating diastolic function in congenital heart disease. *Proc. Natl Acad. Sci. USA* **105**, 5519–5524 (2008).
- Garrity, D. M., Childs, S. & Fishman, M. C. The heartstrings mutation in zebrafish causes heart/fin Tbx5 deficiency syndrome. *Development* **129**, 4635–4645 (2002).
- Biben, C. *et al.* Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. *Circ. Res.* **87**, 888–895 (2000).
- Jay, P. Y. *et al.* Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. *J. Clin. Invest.* **113**, 1130–1137 (2004).
- Stennard, F. A. *et al.* Murine T-box transcription factor Tbx20 acts as a repressor during heart development, and is essential for adult heart integrity, function and adaptation. *Development* **132**, 2451–2462 (2005).
- Reiter, J. F. *et al.* Gata5 is required for the development of the heart and endoderm in zebrafish. *Genes Dev.* **13**, 2983–2995 (1999).
- Mori, A. D. *et al.* Tbx5-dependent rheostatic control of cardiac gene expression and morphogenesis. *Dev. Biol.* **297**, 566–586 (2006).
- Tanaka, M., Chen, Z., Bartunkova, M., Yamazaki, N. & Izumo, S. The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. *Development* **126**, 1269–1280 (1999).
- Durocher, D., Charron, F., Warren, R., Schwartz, R. J. & Nemer, M. The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors. *EMBO J.* **16**, 5687–5696 (1997).
- Yang, D. *et al.* Short RNA duplexes produced by hydrolysis with *Escherichia coli* RNase III mediate effective RNA interference in mammalian cells. *Proc. Natl Acad. Sci. USA* **99**, 9942–9947 (2002).
- Chi, T. H. *et al.* Sequential roles of Brg, the ATPase subunit of BAF chromatin remodeling complexes, in thymocyte development. *Immunity* **19**, 169–182 (2003).
- Gebuhr, T. C. *et al.* The role of Brg1, a catalytic subunit of mammalian chromatin-remodeling complexes, in T cell development. *J. Exp. Med.* **198**, 1937–1949 (2003).
- Seo, S., Richardson, G. A. & Kroll, K. L. The SWI/SNF chromatin remodeling protein Brg1 is required for vertebrate neurogenesis and mediates transactivation of Ngn and NeuroD. *Development* **132**, 105–115 (2005).
- Griffin, C. T., Brennan, J. & Magnuson, T. The chromatin-remodeling enzyme BRG1 plays an essential role in primitive erythropoiesis and vascular development. *Development* **135**, 493–500 (2008).
- Stankunas, K. *et al.* Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. *Dev. Cell* **14**, 298–311 (2008).
- Chi, T. H. *et al.* Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. *Nature* **418**, 195–199 (2002).
- Novak, A., Guo, C., Yang, W., Nagy, A. & Lobe, C. G. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. *Genesis* **28**, 147–155 (2000).
- Srinivas, S. *et al.* Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev. Biol.* **1**, 4 (2001).
- Lakso, M. *et al.* Efficient *in vivo* manipulation of mouse genomic sequences at the zygote stage. *Proc. Natl Acad. Sci. USA* **93**, 5860–5865 (1996).
- Riddle, R. D., Johnson, R. L., Laufer, E. & Tabin, C. Sonic hedgehog mediates the polarizing activity of the ZPA. *Cell* **75**, 1401–1416 (1993).
- Ober, E. A., Verkade, H., Field, H. A. & Stainier, D. Y. Mesodermal Wnt2b signalling positively regulates liver specification. *Nature* **442**, 688–691 (2006).
- Berdougo, E., Coleman, H., Lee, D. H., Stainier, D. Y. & Yelon, D. Mutation of weak atrium/atrial myosin heavy chain disrupts atrial function and influences ventricular morphogenesis in zebrafish. *Development* **130**, 6121–6129 (2003).
- Yelon, D., Horne, S. A. & Stainier, D. Y. Restricted expression of cardiac myosin genes reveals regulated aspects of heart tube assembly in zebrafish. *Dev. Biol.* **214**, 23–37 (1999).
- Irizarry, R. A. *et al.* Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* **4**, 249–264 (2003).
- Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat. Appl. Genet. Mol. Biol.* **3**, Article3 (2004).
- Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. Ser. B* **57**, 289–300 (1995).
- Pollard, K. S. & M. J., van der Laan. in *Bioinformatics and Computational Biology Using R and Bioconductor* (eds Gentleman, R. *et al.*) Ch. 13 Springer, 2005).

Acknowledgments

We thank T. Sukonnik for immunostaining, D. Miguel-Perez for mouse husbandry, S. Izumo and E.N. Olson for providing mice, B. Panning for esiRNA primers and protocols, B.L. Black and D. Srivastava for critical comments on the manuscript, the Gladstone Genomics Core (Y. Hao and L. Ta) and the Gladstone Histology Core (C. Miller and J.-D. Fish) for excellent services, and G. Howard and S. Ordway for editorial assistance. The CH1 monoclonal antibody developed by J.J.C. Lin was obtained from the Developmental Studies Hybridoma Bank, The University of Iowa. This work was supported by a California Institute for Regenerative Medicine Fellowship (P.D.-O.); a Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research fellowship (X.L.); grants

from the NIH/NHLBI (R01 HL54737 to D.Y.R.S., R01 HL085860 to B.G.B.), Human Frontiers Science Program CDA (J.K.T.), Japan Circulation Foundation (J.K.T.), TORAY Foundation (J.K.T. and H.S.) and CIHR Institute of Genetics (Operating Grant 86663 to I.C.S.). B.G.B. is the recipient of the Lawrence J. and Florence A. DeGeorge Charitable Trust/American Heart Association Established Investigator Award. This work was also supported by an NIH/NCRR grant (C06 RR018928) to the J. David Gladstone Institutes and by William H. Younger, Jr (B.G.B.).

Author contributions

J.K.T. and B.G.B. designed the study. J.K.T. performed most of the work on mice. X.L. carried out most of the work on zebrafish, under the direction of I.C.S. C.M. isolated the zebrafish *brg1* mutation under the direction of D.Y.R.S. J.M.A. and P.D.-O. performed cell culture assays. H.S. performed chromatin immunoprecipitation under the direction of J.K.T. A.K.H., R.-F.Y. and K.S.P. designed and performed bioinformatics analysis of array data. RNA isolation and preparation were performed by A.D.M. and J.N.W. R.P.H., D.M. and P.C. provided genetically modified mouse strains. Y.Z. and Y.-Q.Z. performed mouse physiological measurements under the direction of B.G.B. and R.M.H., respectively. B.G.B. wrote the paper with contributions from all authors.

Additional information

Accession codes: Microarray data have been deposited in GEO under the accession number GSE26191.

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Takeuchi, J. K. *et al.* Chromatin remodelling complex dosage modulates transcription factor function in heart development. *Nat. Commun.* 2:187 doi: 10.1038/ncomms1187 (2011).

License: This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>